NASDAQ:XBIT - XBiotech Stock Price, Price Target & More

$4.83 -0.03 (-0.62 %)
(As of 04/24/2018 02:53 AM ET)
Previous Close$4.86
Today's Range$4.80 - $4.89
52-Week Range$2.77 - $11.85
Volume40,403 shs
Average Volume74,278 shs
Market Capitalization$172.24 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71

About XBiotech (NASDAQ:XBIT)

XBiotech logoXBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2930

Debt

Debt-to-Equity RatioN/A
Current Ratio11.95%
Quick Ratio11.95%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book2.84

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-33,150,000.00
Net MarginsN/A
Return on Equity-46.91%
Return on Assets-44.34%

Miscellaneous

Employees51
Outstanding Shares35,440,000

How to Become a New Pot Stock Millionaire

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

How were XBiotech's earnings last quarter?

XBiotech (NASDAQ:XBIT) issued its quarterly earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.08. View XBiotech's Earnings History.

When is XBiotech's next earnings date?

XBiotech is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for XBiotech.

Who are some of XBiotech's key competitors?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:
  • Mr. John Simard, Founder, Chairman, Chief Exec. Officer and Pres (Age 56)
  • Dr. Michael Stecher M.D., Medical Director (Age 41)
  • Ms. Queena Han, VP of Fin. & HR and Sec. (Age 51)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 62)
  • Dr. Sushma Shivaswamy Ph.D., Chief Scientific Officer (Age 40)

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

Has XBiotech been receiving favorable news coverage?

Media coverage about XBIT stock has trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. XBiotech earned a coverage optimism score of 0.11 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.96 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $4.83.

How big of a company is XBiotech?

XBiotech has a market capitalization of $172.24 million. XBiotech employs 51 workers across the globe.

How can I contact XBiotech?

XBiotech's mailing address is 8201 E. RIVERSIDE DRIVE BUILDING 4 SUITE 100, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2930 or via email at [email protected]


MarketBeat Community Rating for XBiotech (XBIT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

XBiotech (NASDAQ:XBIT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for XBiotech in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$13.00$13.00$13.00
Price Target Upside: N/A27.33% upside27.33% upside27.33% upside

XBiotech (NASDAQ:XBIT) Consensus Price Target History

Price Target History for XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ:XBIT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2017Stifel NicolausUpgradeHold -> BuyHighView Rating Details
4/21/2017Noble FinancialReiterated RatingBuy -> Hold$13.00HighView Rating Details
(Data available from 4/24/2016 forward)

Earnings

XBiotech (NASDAQ:XBIT) Earnings History and Estimates Chart

Earnings by Quarter for XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ XBIT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
5/10/2017Q1 2017($0.47)($0.32)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.42)($0.51)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.46)($0.38)ViewListenView Earnings Details
8/12/2016Q2 2016($0.35)($0.42)ViewN/AView Earnings Details
5/18/2016Q1 2016($0.39)($0.32)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.35)($0.37)ViewN/AView Earnings Details
11/12/2015Q3($0.21)($0.33)ViewListenView Earnings Details
8/14/2015Q2 2015($0.22)ViewN/AView Earnings Details
5/27/2015Q1 2015($0.29)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

XBiotech (NASDAQ:XBIT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

XBiotech (NASDAQ XBIT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 9.27%
Insider Trading History for XBiotech (NASDAQ:XBIT)
Insider Trading History for XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ XBIT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/23/2018Queena HanVPSell80,000$4.73$378,400.009,599View SEC Filing  
3/21/2018Queena HanVPSell9,599$4.48$43,003.529,599View SEC Filing  
11/15/2016Queena HanVPSell19,573$15.00$293,595.0019,573View SEC Filing  
9/8/2016Queena HanVPSell427$15.00$6,405.00427View SEC Filing  
5/26/2016W Thorpe MckenzieDirectorBuy20,000$13.96$279,200.003,898,600View SEC Filing  
5/20/2016W Thorpe MckenzieDirectorBuy1,500$13.75$20,625.003,898,600View SEC Filing  
12/22/2015Queena HanVPSell30,000$10.39$311,700.00View SEC Filing  
11/16/2015Michael StecherDirectorSell1,800$14.00$25,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

XBiotech (NASDAQ XBIT) News Headlines

Source:
DateHeadline
BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In DermatologyBRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
www.reuters.com - April 16 at 9:37 AM
XBiotech Announces Upcoming Phase 2 Clinical Studies in DermatologyXBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology
finance.yahoo.com - April 16 at 9:37 AM
XBiotech (XBIT) Announces License from CT Atlantic AG for Anti-NY-ESO-1 Antibody Targeting Advanced CancerXBiotech (XBIT) Announces License from CT Atlantic AG for Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
www.streetinsider.com - April 3 at 10:01 AM
XBiotech, Inc: XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced CancerXBiotech, Inc: XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
www.finanznachrichten.de - April 2 at 10:10 AM
XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced CancerXBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
finance.yahoo.com - April 2 at 10:10 AM
Insider Selling: XBiotech Inc (XBIT) VP Sells 9,599 Shares of StockInsider Selling: XBiotech Inc (XBIT) VP Sells 9,599 Shares of Stock
www.americanbankingnews.com - March 26 at 4:12 PM
Queena Han Sells 80,000 Shares of XBiotech Inc (XBIT) StockQueena Han Sells 80,000 Shares of XBiotech Inc (XBIT) Stock
www.americanbankingnews.com - March 26 at 4:10 PM
Comparing Athenex (ATNX) & XBiotech (XBIT)Comparing Athenex (ATNX) & XBiotech (XBIT)
www.americanbankingnews.com - March 3 at 7:22 PM
Active-Investors: Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF ConferenceActive-Investors: Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF Conference
www.finanznachrichten.de - January 29 at 4:34 PM
Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF ConferenceBlog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF Conference
finance.yahoo.com - January 29 at 9:05 AM
XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaXBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
finance.yahoo.com - January 26 at 9:04 AM
XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureusXBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus
finance.yahoo.com - January 25 at 8:59 AM
Blog Exposure - XBiotech to Present Phase-2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa at EHSF ConferenceBlog Exposure - XBiotech to Present Phase-2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa at EHSF Conference
finance.yahoo.com - January 22 at 5:39 PM
XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment ... - GlobeNewswire (press release)XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment ... - GlobeNewswire (press release)
globenewswire.com - January 19 at 12:00 PM
XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaXBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
finance.yahoo.com - January 19 at 12:00 PM
Financial Analysis: XBiotech (XBIT) vs. Its PeersFinancial Analysis: XBiotech (XBIT) vs. Its Peers
www.americanbankingnews.com - January 7 at 7:28 AM
Winners, losers: The 5 best and 5 worst performing Austin-area stocks of 2017Winners, losers: The 5 best and 5 worst performing Austin-area stocks of 2017
www.bizjournals.com - January 6 at 10:25 AM
Cynapsus Therapeutics (CYNA) & XBiotech (XBIT) Head-To-Head ComparisonCynapsus Therapeutics (CYNA) & XBiotech (XBIT) Head-To-Head Comparison
www.americanbankingnews.com - January 3 at 5:34 PM
Analyzing XBiotech (XBIT) and Its CompetitorsAnalyzing XBiotech (XBIT) and Its Competitors
www.americanbankingnews.com - January 1 at 3:28 AM
Reviewing XBiotech (XBIT) & The CompetitionReviewing XBiotech (XBIT) & The Competition
www.americanbankingnews.com - December 29 at 7:24 PM
Financial Contrast: XBiotech (XBIT) vs. Its RivalsFinancial Contrast: XBiotech (XBIT) vs. Its Rivals
www.americanbankingnews.com - December 19 at 7:10 PM
Short Interest in XBiotech Inc. (XBIT) Decreases By 2.2%Short Interest in XBiotech Inc. (XBIT) Decreases By 2.2%
www.americanbankingnews.com - December 18 at 4:36 PM
Contrasting XBiotech (XBIT) & Revance Therapeutics (RVNC)Contrasting XBiotech (XBIT) & Revance Therapeutics (RVNC)
www.americanbankingnews.com - December 17 at 1:50 AM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
finance.yahoo.com - December 11 at 4:38 PM
Critical Analysis: XBiotech (XBIT) & Its RivalsCritical Analysis: XBiotech (XBIT) & Its Rivals
www.americanbankingnews.com - December 11 at 8:08 AM
Critical Review: XBiotech (XBIT) versus Its PeersCritical Review: XBiotech (XBIT) versus Its Peers
www.americanbankingnews.com - December 9 at 7:18 PM
XBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 StudyXBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study
www.streetinsider.com - December 5 at 4:25 PM
XBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study - StreetInsider.comXBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study - StreetInsider.com
www.streetinsider.com - December 4 at 4:27 PM
Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark ... - PR Newswire (press release)Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark ... - PR Newswire (press release)
www.prnewswire.com - November 18 at 10:26 AM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
finance.yahoo.com - November 18 at 10:26 AM
XBiotech (XBIT) Announces Presentation of Novel Findings for MABp1 in Prevention of Coronary Thrombosis at AHA - StreetInsider.comXBiotech (XBIT) Announces Presentation of Novel Findings for MABp1 in Prevention of Coronary Thrombosis at AHA - StreetInsider.com
www.streetinsider.com - November 16 at 8:57 AM
XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech ...XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech ...
www.businesswire.com - November 9 at 10:17 AM
XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.
finance.yahoo.com - November 9 at 10:17 AM
XBiotech (XBIT) Says Its MABp1 to be Featured in Oral Presentation ... - StreetInsider.comXBiotech (XBIT) Says Its MABp1 to be Featured in Oral Presentation ... - StreetInsider.com
www.streetinsider.com - November 5 at 8:19 AM
XBiotechs MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific SessionsXBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
feeds.benzinga.com - November 3 at 12:58 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered ... - GlobeNewswire (press release)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered ... - GlobeNewswire (press release)
globenewswire.com - October 27 at 10:09 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in XBiotech, Inc. and Set a Lead Plaintiff Deadline of December 26, 2017 -- XBITSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in XBiotech, Inc. and Set a Lead Plaintiff Deadline of December 26, 2017 -- XBIT
finance.yahoo.com - October 27 at 7:43 AM
XBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 Combo with Onivyde and 5-fluorouracil/folinic acid for Treatment of Pancreatic CancerXBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 Combo with Onivyde and 5-fluorouracil/folinic acid for Treatment of Pancreatic Cancer
www.streetinsider.com - October 20 at 10:33 AM
XBiotech Enters Oversold Territory (XBIT)XBiotech Enters Oversold Territory (XBIT)
www.thestreet.com - October 20 at 10:33 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBITINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
finance.yahoo.com - October 20 at 10:33 AM
XBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 ... - StreetInsider.comXBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 ... - StreetInsider.com
www.streetinsider.com - October 18 at 9:49 PM
Comparing Acer Therapeutics (ACER) & XBiotech (XBIT)Comparing Acer Therapeutics (ACER) & XBiotech (XBIT)
www.americanbankingnews.com - October 18 at 2:24 PM
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic CancerXBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
finance.yahoo.com - October 18 at 10:53 AM
XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory BoardXBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board
finance.yahoo.com - October 3 at 3:31 PM
XBiotech to Present at Cantor Fitzgeralds Global Healthcare ConferenceXBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference
finance.yahoo.com - September 23 at 12:14 PM
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination withXBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with
www.nasdaq.com - September 20 at 11:22 AM
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic CancerXBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
finance.yahoo.com - September 20 at 11:22 AM
Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc.Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc.
www.thestreet.com - September 19 at 9:47 AM
Contrasting XBiotech (XBIT) & Lexicon Pharmaceuticals (LXRX)Contrasting XBiotech (XBIT) & Lexicon Pharmaceuticals (LXRX)
www.americanbankingnews.com - September 15 at 4:34 AM
XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis ... - GlobeNewswire (press release)XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis ... - GlobeNewswire (press release)
globenewswire.com - September 7 at 11:29 AM

SEC Filings

XBiotech (NASDAQ:XBIT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

XBiotech (NASDAQ:XBIT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

XBiotech (NASDAQ XBIT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.